Cleviprex is an intravenous dihydropyridine calcium channel blocker, which helps in reduction of blood pressure when oral therapy is not feasible. According to the company, the new formulation
Miravirsen, which is developed using Locked Nucleic Acid (LNA) Drug Platform, is an inhibitor of miR-122, a liver specific microRNA that the Hepatitis C virus requires for replication.
A web-based repository has been developed by ICON, which will help facilitate analysis of clinical trial data, thereby resulting in better efficiency across the business, siliconrepublic.com reported. Oracle
SEP has acquired a minority stake in Exco InTouch which will use the funds to drive its growth in the clinical technology sector, especially in the mobile patient
Galapagos will develop new candidate drugs against the targets. As per the agreement, Servier can exclusively license each small molecule program after the completion of pre-clinical development by
Russian government has signed the agreement on behalf of Volgograd State Medical University, which will work with NIPER on pharmaceutical research, pharmabiz.com reported. NIPER director Professor KK Bhutani
According to the company, Stopain provides temporary relief for minor pains, muscle aches and stiffness commonly associated with arthritis. The product will be available as Stopain Extra Strength
IB1001 is a recombinant factor IX (FIX) product, which helps prevent bleeding in individuals with hemophilia B. The MAA comprises the data from the clinical program for IB1001,
The program requires ClinicalRM to provide an infrastructure of personnel, materials, equipment, facilities, science, and technology that will sustain an acceptable level of medical research. The Omnibus III
VGX-100 is a human antibody that acts against the human VEGF-C protein and is used to treat glioblastoma and metastatic colorectal cancers. Circadian is also developing VGX-100 for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.